Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
← catalyst calendarNCT03319940 · readout in 134 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
269actual
Sites
39
Countries
Australia, Austria, France +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-12-26 | actual | When the study began enrolling |
| Primary completion | 2026-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2017-10-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Small Cell Lung Carcinoma
Interventions
- Drug: Tarlatamab
- Drug: Pembrolizumab
- Drug: CRS Mitigation Strategies
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with dose limiting toxicities (DLT) for all indications
measured 6 months
Number of participants with treatment-emergent adverse events (AEs) for all indications
measured 4 years
Number of participants with treatment-related AEs for all indications
measured 4 years
Number of participants with clinically significant changes in vital signs for all indications
measured 4 years
Number of participants with significant changes in electrocardiogram (ECG) for all indications
measured 4 years
Number of participants with significant changes in physical examinations for all indications
measured 4 years
Number of participants with significant changes in clinical laboratory tests for all indications
measured 4 years
Publications
- PMID 31215500 — cited as background
- PMID 39208379 — cited as background
- PMID 36689692 — cited as background
- PMID 40187110 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed